TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS

Acute Respiratory Distress Syndrome (ARDS) is a type of respiratory failure with low blood oxygen concentrations, usually caused by diffuse alveolar damage (DAD) that begins with the detachment of pneumocytes from the alveolar wall. Sepsis, such as that which aggravated COVID-19, is the most common cause of ARDS, a disorder that typically affects humans. ARDS, which seriously compromises the patient's life, does not have a specific treatment and generic life-support treatments are used, which are relatively ineffective and not free of toxicity, with mortality rates of up to 50% in developed countries. Only some of the remedies for ARDS are marketed at high prices. Therefore, there is a need to find new remedies that are economically sustainable, more effective and with fewer adverse effects.